Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)
NCT ID: NCT02231736
Last Updated: 2014-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
130 participants
OBSERVATIONAL
2014-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Mortality and Cardiovascular Diseases in Adult-onset Type 1 Diabetes
NCT06563401
Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients
NCT01781754
Time To Complications Occurs in Diabetes
NCT00969956
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)
NCT04139369
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
NCT03566511
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetes, HbA1c>7.5
No interventions assigned to this group
Type 2 diabetes, HbA1c<7.5
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sex: female
* Age: \> 30years
* Medication: oral anti-diabetics and/or Insulin therapy
* Constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks
* Non-smoking for at least 1 year
Exclusion Criteria
* Age: \< 30years
* Pregnant or lactating women
* Participation in another clinical trial
* Change of medication in regard to metabolic parameters within the last 4 weeks
* Significant cardiovascular damage with NYHA \> III
* Liver disease with three-times higher transaminase values
* Chronic kidney disease with serum creatinine \> 2 mg/dl
* Dialysis
* HIV positive
* History of chronic alcohol abuse in the last two years
* History of cancer, stroke, organ transplantation
* Male
30 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vienna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karl-Heinz Wagner
Director Research Platform Active Ageing
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karl-Heinz Wagner, PhD
Role: PRINCIPAL_INVESTIGATOR
UNIVIE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Milic M, Ceppi M, Bruzzone M, Azqueta A, Brunborg G, Godschalk R, Koppen G, Langie S, Moller P, Teixeira JP, Alija A, Anderson D, Andrade V, Andreoli C, Asllani F, Bangkoglu EE, Barancokova M, Basaran N, Boutet-Robinet E, Buschini A, Cavallo D, Costa Pereira C, Costa C, Costa S, Da Silva J, Del Bo' C, Dimitrijevic Sreckovic V, Djelic N, Dobrzynska M, Durackova Z, Dvorakova M, Gajski G, Galati S, Garcia Lima O, Giovannelli L, Goroshinskaya IA, Grindel A, Gutzkow KB, Hernandez A, Hernandez C, Holven KB, Ibero-Baraibar I, Ottestad I, Kadioglu E, Kazimirova A, Kuznetsova E, Ladeira C, Laffon B, Lamonaca P, Lebailly P, Louro H, Mandina Cardoso T, Marcon F, Marcos R, Moretti M, Moretti S, Najafzadeh M, Nemeth Z, Neri M, Novotna B, Orlow I, Paduchova Z, Pastor S, Perdry H, Spremo-Potparevic B, Ramadhani D, Riso P, Rohr P, Rojas E, Rossner P, Safar A, Sardas S, Silva MJ, Sirota N, Smolkova B, Staruchova M, Stetina R, Stopper H, Surikova EI, Ulven SM, Ursini CL, Valdiglesias V, Valverde M, Vodicka P, Volkovova K, Wagner KH, Zivkovic L, Dusinska M, Collins AR, Bonassi S. The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders. Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108371. doi: 10.1016/j.mrrev.2021.108371. Epub 2021 Feb 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UNIVIE-549-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.